First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

AI Briefing

• – New data shows positive real-world impact of Eversense 365 CGM, demonstrated through strong patient adherence and positive health outcomes over one year.
• – The device's one-year wear resulted in sustained performance and a significant reduction in hypoglycemic events.
• – Eversense 365 is the world's first and only one-year continuous glucose monitoring system.